Yunfang Wang

Yunfang Wang


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2023 in Science China Life Sciences
Verified
Journal Article
Closed access
HBHainan Bao
Hainan Bao
JCJiani Cao
Jiani Cao
MCMengting Chen
Mengting Chen
MCMin Chen
Min Chen
WCWei Chen
Wei Chen
GLGuang-Hui Liu
Guang-Hui Liu

24 April 2018 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
JLJuan Liu
Juan Liu
ZCZhiqiang Chen
Zhiqiang Chen
JWJie Wang
Jie Wang
RLRuihong Li
Ruihong Li
TLTingting Li
Tingting Li
YWYunfang Wang
Yunfang Wang

18 October 2019 in Cell Research
Verified
Journal Article
Closed access
PDF file
SWShuyong Wang
Shuyong Wang
XWXuan Wang
Xuan Wang
ZTZuolong Tan
Zuolong Tan
YSYuxin Su
Yuxin Su
JLJuan Liu
Juan Liu
YWYunfang Wang
Yunfang Wang

11 April 2024 in Exploration
Verified
Journal Article
Open access
JLJuan Liu
Juan Liu
QSQingru Song
Qingru Song
WYWenzhen Yin
Wenzhen Yin
CLChen Li
Chen Li
NANi An
Ni An
YWYunfang Wang
Yunfang Wang
Decellularized extracellular matrix (dECM) offers a three‐dimensional, non‐immunogenic scaffold, enriched with bioactive components, making it a suitable candidate for tissue regeneration. Although dECM‐based scaffolds have been successfully implemented in preclinical and clinical settings within tissue engineering and regenerative medicine, the mechanisms of tissue remodeling and functional restoration are not fully understood. This review critically assesses the state‐of‐the‐art in dECM scaffolds, including decellularization techniques for various tissues, quality control and cross‐linking. It highlights the functional properties of dECM components and their latest applications in multiorgan tissue engineering and biomedicine. Additionally, the review addresses current challenges and limitations of decellularized scaffolds and offers perspectives on future directions in the field.

11 March 2019 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
JDJinmei Diao
Jinmei Diao
JLJuan Liu
Juan Liu
SWShuyong Wang
Shuyong Wang
MCMingyang Chang
Mingyang Chang
XWXuan Wang
Xuan Wang
YWYunfang Wang
Yunfang Wang
Sweat glands perform a vital thermoregulatory function in mammals. Like other skin components, they originate from epidermal progenitors. However, they have low regenerative potential in response to injury. We have established a sweat gland culture and expansion method using 3D organoids cultures. The epithelial cells derived from sweat glands in dermis of adult mouse paw pads were embedded into Matrigel and formed sweat gland organoids (SGOs). These organoids maintained remarkable stem cell features and demonstrated differentiation capacity to give rise to either sweat gland cells (SGCs) or epidermal cells. Moreover, the bipotent SGO-derived cells could be induced into stratified epidermis structures at the air−liquid interface culture in a medium tailored for skin epidermal cells in vitro. The SGCs embedded in Matrigel tailored for sweat glands formed epithelial organoids, which expressed sweat-gland-specific markers, such as cytokeratin (CK) 18 and CK19, aquaporin (AQP) 5 and αATP. More importantly, they had potential of regeneration of epidermis and sweat gland when they were transplanted into the mouse back wound and claw pad with sweat gland injury, respectively. In summary, we established and optimized culture conditions for effective generation of mouse SGOs. These cells are candidates to restore impaired sweat gland tissue as well as to improve cutaneous skin regeneration.

19 July 2013 in Stem Cells
Verified
Journal Article
Open access
PDF file
GLGiacomo Lanzoni
Giacomo Lanzoni
TOTsunekazu Oikawa
Tsunekazu Oikawa
YWYunfang Wang
Yunfang Wang
CCCai-Bin Cui
Cai-Bin Cui
GCGuido CARPINO
Guido CARPINO
Lola M. ReidLola M. Reid
Lola M. Reid
Regenerative medicine is transitioning into clinical programs using stem/progenitor cell therapies for repair of damaged organs. We summarize those for liver and pancreas, organs that share endodermal stem cell populations, biliary tree stem cells (hBTSCs), located in peribiliary glands. They are precursors to hepatic stem/progenitors in canals of Hering and to committed progenitors in pancreatic duct glands. They give rise to maturational lineages along a radial axis within bile duct walls and a proximal‐to‐distal axis starting at the duodenum and ending with mature cells in the liver or pancreas. Clinical trials have been ongoing for years assessing effects of determined stem cells (fetal‐liver‐derived hepatic stem/progenitors) transplanted into the hepatic artery of patients with various liver diseases. Immunosuppression was not required. Control subjects, those given standard of care for a given condition, all died within a year or deteriorated in their liver functions. Subjects transplanted with 100‐150 million hepatic stem/progenitor cells had improved liver functions and survival extending for several years. Full evaluations of safety and efficacy of transplants are still in progress. Determined stem cell therapies for diabetes using hBTSCs remain to be explored but are likely to occur following ongoing preclinical studies. In addition, mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs) are being used for patients with chronic liver conditions or with diabetes. MSCs have demonstrated significant effects through paracrine signaling of trophic and immunomodulatory factors, and there is limited evidence for inefficient lineage restriction into mature parenchymal or islet cells. HSCs' effects are primarily via modulation of immune mechanisms. Stem Cells 2013;31:2047–2060